Curcumin and a hemi-analogue with improved blood-brain barrier permeability protect against amyloid-beta toxicity in Caenorhabditis elegans via SKN-1/Nrf activation.
Elaine Hui-Chien LeeSherlyn Sheau-Chin LimKah-Hay YuenChong-Yew LeePublished in: The Journal of pharmacy and pharmacology (2018)
Analogue C4 provides a new lead for the development of a curcumin-based compound for protection against Aβ toxicity with an improved BBB permeability.